Findings

What do systematic reviews say?

5 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 66.7%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Low molecular weight heparin and idraparinux vs usual care

Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin and idraparinux vs usual care

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.51 [0.26, 8.9]
1 study · 263 participants
Very low

Low molecular weight heparin and idraparinux vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

2 findings from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 3.76 [0.5, 28.19]
1 study · 659 participants
Very low

Low molecular weight heparin and idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin and idraparinux vs usual care

All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found